This document is a USPTO patent application (US20260083727A1) for pharmaceutical formulations of nintedanib intended for intraocular use, specifically for treating back-of-the-eye diseases. The application details formulations and intravitreal implants containing nintedanib and lists six inventors. The filing date was August 11, 2023.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signifies potential future intellectual property rights related to nintedanib-based treatments for ophthalmic conditions. Companies operating in the pharmaceutical and medical device sectors, particularly those involved in ophthalmology, should be aware of this filing as it may impact their research, development, and commercialization strategies in this therapeutic area.